1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors: lead optimization studies resulting in the identification of N-(1-(2-(methylamino)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide as a preclinical development candidate.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2012-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm3000449PMID 22335555
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 1,5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase inhibitors.

  2011cited by this paper
• Discovery of N-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a selective inhibitor of human neuronal nitric oxide synthase (nNOS) for the treatment of pain.

  2011cited by this paper
• Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors.

  2011cited by this paper
• 1,6-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase inhibitors.

  2011cited by this paper
• Symmetric double-headed aminopyridines, a novel strategy for potent and membrane-permeable inhibitors of neuronal nitric oxide synthase.

  2011cited by this paper
• Increased nitric oxide stress is associated with migraine

  2010cited by this paper
• Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.

  2010cited by this paper
• Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS

  2010cited by this paper
• Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of a cerebral palsy phenotype in an animal model.

  2010cited by this paper
• Measurement of Phosphorylated Extracellular Signal–Regulated Kinase 1 and 2 in an Undergraduate Teaching Laboratory with ALPHAscreen Technology

  2009cited by this paper
• Pharmacological assessments of nitric oxide synthase isoforms and downstream diversity of NO signaling in the maintenance of thermal and mechanical hypersensitivity after peripheral nerve injury in mice.

  2009cited by this paper
• Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases.

  2009cited by this paper
• Chapter 2 Advancements in the Development of Nitric Oxide Synthase Inhibitors

  2009cited by this paper
• Nitric oxide and pain: ‘Something old, something new’

  2009cited by this paper
• Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors.

  2008cited by this paper
• Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity

  2007cited by this paper
• Ligand efficiency indices for effective drug discovery

  2007cited by this paper
• A quantitative assessment of hERG liability as a function of lipophilicity.

  2007cited by this paper
• Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors.

  2007cited by this paper
• Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development.

  2006cited by this paper
• Nitric Oxide and Cyclic GMP in Cell Signaling and Drug Development

  2006cited by this paper
• Selective neuronal nitric oxide synthase inhibitors.

  2005cited by this paper
• The impact of drug-induced QT interval prolongation on drug discovery and development

  2003cited by this paper
• A dose–response study of nitric oxide synthase inhibition in different vascular beds in man

  2003cited by this paper
• A comparison of physiochemical property profiles of development and marketed oral drugs.

  2003cited by this paper
• Blocking NO synthesis: how, where and why?

  2002cited by this paper
• Drug-like properties and the causes of poor solubility and poor permeability.

  2000cited by this paper
• Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone?

  1998cited by this paper
• Structure-function aspects in the nitric oxide synthases.

  1997cited by this paper
• The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide.

  1996cited by this paper
• Hypertension in mice lacking the gene for endothelial nitric oxide synthase

  1995cited by this paper
• An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat

  1992cited by this paper
• Nitric oxide: physiology, pathophysiology, and pharmacology.

  1991cited by this paper
• Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.

  1987cited by this paper

• Ni0/Niδ+ Synergistic Catalysis on a Nanosized Ni Surface for Simultaneous Formation of C–C and C–N Bonds

  2019cites this paper
• An efficient and convenient route for the synthesis of thiophene-2-carboxamidines as potential inhibitors of nitric oxide synthase (NOS)

  2019cites this paper
• Structural Basis for Isoform Selective Nitric Oxide Synthase Inhibition by Thiophene-2-carboximidamides.

  2018cites this paper
• Neurons derived from different brain regions are inherently different in vitro: a novel multiregional brain-on-a-chip.

  2017cites this paper
• Amidine-Based Compounds Affecting l-Arginine Metabolism

  2017cites this paper
• Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.

  2015cites this paper
• Computational development of selective nNOS inhibitors: binding modes and pharmacokinetic considerations.

  2015cites this paper
• 2-Aminopyridines with a Truncated Side Chain To Improve Human Neuronal Nitric Oxide Synthase Inhibitory Potency and Selectivity.

  2015cites this paper
• The Discovery of Potentially Selective Human Neuronal Nitric Oxide Synthase (nNOS) Inhibitors: A Combination of Pharmacophore Modelling, CoMFA, Virtual Screening and Molecular Docking Studies

  2014cites this paper
• Potent and Selective Double-Headed Thiophene-2-carboximidamide Inhibitors of Neuronal Nitric Oxide Synthase for the Treatment of Melanoma

  2014cites this paper
• Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain.

  2014cites this paper
• The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer

  2014cites this paper
• Recent advances toward improving the bioavailability of neuronal nitric oxide synthase inhibitors.

  2013cites this paper
• Amidine-based bioactive compounds for the regulation of arginine metabolism.

  2013cites this paper
• Structure-guided design of selective inhibitors of neuronal nitric oxide synthase.

  2013cites this paper
• A behavioural evaluation of the potential of nNOS inhibitors to control dyskinesia in animal models of Parkinson's disease

  2012cites this paper